Lipofoods SLU will introduce a high bioavailability, microencapsulated curcumin ingredient for the nutricosmetic market called Curcushine at Vitafoods Europe in Geneva.
Photo © Shutterstock.com/goodluz
Lipofoods SLU (Barcelona, Spain) will introduce a high bioavailability, microencapsulated curcumin ingredient for the nutricosmetic market called Curcushine at Vitafoods Europe in Geneva. The Curcushine microcapsules are natural, vegan, and have high solubility when dissolved in water. The product was created in collaboration with Sphera Encapsulation S.R.L. Sphera, an Italian research and development company dedicated to nano- and microencapsulation strategies. As part of this collaboration, Lipofoods has a licensing agreement to market Curcushine.
“Partnering with Sphera is a strategic move that opens new opportunities for Lipofoods to launch advanced botanical formulations that have a cutting-edge advantage,” said David Padro, business manager of Lipofoods, in a press release. “Lipofoods is engaged in ongoing research into the anti-aging benefits and other health condition benefits of Curcushine microencapsulated curcumin, seeking out new markets and different food applications.”
Curcumin supports skin health by protecting it from oxidative stress and inflammation. The solubility of curcumin has long been a challenge for the herb, but through Sphera’s innovative technology that turns hydrophobic active ingredients into soluble microcapsules via coating materials and processing, Curcushine has the ability to more directly compete with collagen products.
“Curcushine microcapsules provides anti-aging benefits and is suitable for multiple nutraceutical applications,” said Isabel Gomez, marketing manager of Lipofoods, in a press release. “We plan to showcase beauty gummies containing Curcushine microcapsules in our booth at Vitafoods and we will also perform live demos to demonstrate the product´s high solubility.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.